Analysis of the profitability of adult vaccination in 13 private provider practices in the United States.
Adult vaccination
Barriers to vaccination
Economic analysis
Financial analysis
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
30 09 2019
30 09 2019
Historique:
received:
04
03
2019
revised:
21
08
2019
accepted:
22
08
2019
pubmed:
10
9
2019
medline:
22
9
2020
entrez:
10
9
2019
Statut:
ppublish
Résumé
Vaccination coverage among adults remains low in the United States. Understanding the barriers to provision of adult vaccination is an important step to increasing vaccination coverage and improving public health. To better understand financial factors that may affect practice decisions about adult vaccination, this study sought to understand how costs compared with payments for adult vaccinations in a sample of U.S. physician practices. We recruited a convenience sample of 19 practices in nine states in 2017. We conducted a time-motion study to assess the time costs of vaccination activities and conducted a survey of practice managers to assess materials, management, and dose costs and payments for vaccination. We received complete cost and payment data from 13 of the 19 practices. We calculated annual income from vaccination services by comparing estimated costs with payments received for vaccine doses and vaccine administration. Median annual total income from vaccination services was $90,343 at family medicine practices (range: $3968-$249,628), $28,267 at internal medicine practices (-$32,659-$141,034) and $2886 at obstetrics and gynecology practices (-$73,451-$23,820). Adult vaccination was profitable at the median of our sample, but there is wide variation in profitability due to differences in costs and payment rates across practices. This study provides evidence on the financial viability of adult vaccination and supports actions for improving financial viability. These results can help inform practices' decisions whether to provide adult vaccines and contribute to keeping adults up-to-date with the recommended vaccination schedule.
Identifiants
pubmed: 31495594
pii: S0264-410X(19)31130-2
doi: 10.1016/j.vaccine.2019.08.056
pmc: PMC6778689
mid: NIHMS1049380
pii:
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
6180-6185Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Ann Intern Med. 2019 Feb 5;170(3):182-92
pubmed: 30716757
Vaccine. 2019 Feb 4;37(6):792-797
pubmed: 30639460
Ann Intern Med. 2014 Feb 4;160(3):161
pubmed: 24658693
MMWR Morb Mortal Wkly Rep. 2014 Apr 25;63(16):352-5
pubmed: 24759657
Am J Prev Med. 2016 Dec;51(6):1079-1083
pubmed: 27236479
Obstet Gynecol Surv. 2009 Dec;64(12):823-9
pubmed: 19939296
MMWR Surveill Summ. 2017 May 05;66(11):1-28
pubmed: 28472027
Public Health Rep. 2012 Jan-Feb;127 Suppl 1:1-42
pubmed: 22210957
Ann Intern Med. 2018 Feb 6;168(3):210-220
pubmed: 29404596
Vaccine. 2016 Sep 30;34(42):5060-5065
pubmed: 27614782
Vaccine. 2017 Jan 23;35(4):647-654
pubmed: 28024954
Health Aff (Millwood). 2016 Nov 1;35(11):2124-2132
pubmed: 27733424
Vaccine. 2018 Feb 14;36(8):1093-1100
pubmed: 29366706